Starlight Cardiovascular Awarded $2M NIH SBIR Phase II Grant to Develop Pediatric Cardiology Device
Award supports design and preclinical testing of Pulmonary Flow Restrictor for Congenital Heart Disease
SAN DIEGO, May 1, 2024 /PRNewswire/ — Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of its Pulmonary Flow Restrictor. The award will provide $1,999,870 to support preclinical testing of a device that is designed to prevent detrimental over-circulation to the lungs in babies born with Congenital Heart Disease (CHD).
